最新！10款医疗器械进入创新通道

Core Viewpoint - The article discusses the recent approval of 10 innovative medical devices by the National Medical Products Administration (NMPA) in China, highlighting the advancements in the medical technology sector and the companies involved in these innovations [1]. Group 1: Innovative Medical Devices - The first product is a software for assessing chronic obstructive pulmonary disease, developed by Bojiang Life Sciences (Shanghai) Co., Ltd., which focuses on digital biomarkers and therapies for chronic disease management [2]. - The second product is an ultrasound therapy device from Shenzhen Tengfu Medical Technology Co., Ltd., which specializes in interventional devices for pulmonary embolism treatment [3]. - The third product is a transcatheter artificial tricuspid valve developed by Edwards Lifesciences, a leading company in structural heart disease devices [4][5]. - The fourth product is an ultrasound thrombolysis catheter and stent system from Shanghai Tengfu Medical Technology Co., Ltd., aimed at providing safer treatment options for venous thromboembolism [9][11]. - The fifth product is a radiation therapy planning software from Guoke Ion Medical Technology Co., Ltd., which focuses on the industrialization of medical heavy ion technology [12]. - The sixth product is an implantable cardioverter-defibrillator from Chuangling Heart Rhythm Management Medical Device (Shanghai) Co., Ltd., which aims to provide high-quality heart rhythm management products [13]. - The seventh product is a peripheral balloon-expandable stent system from Zhejiang Guichuang Medical Technology Co., Ltd., which specializes in high-end vascular interventional devices [14]. - The eighth product is a thoracoabdominal endoscopic surgical system from Intuitive Surgical, a global leader in robotic-assisted minimally invasive surgery [15][16]. - The ninth product is a coronary sinus balloon counterpulsation system from Shanghai Micron Melody Medical Technology Co., Ltd., which focuses on coronary intervention devices [17].